Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, physician nephrology, ambulant treatment, and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an)

In a report released today, Falko Friedrichs from Deutsche Bank maintained a Hold rating on Fresenius Medical Care AG & Co. KGaA, with a price targ...

Fresenius Medical Care AG & Co. KGaA (0H9X) Receives a Hold from Deutsche Bank

Morgan Stanley analyst Aisyah Noor maintained a Sell rating on Fresenius Medical Care AG & Co. KGaA today and set a price target of €32.00. Accordi...

Morgan Stanley Keeps Their Sell Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

Jefferies analyst James Vane maintained a Sell rating on Fresenius Medical Care AG & Co. KGaA today and set a price target of €31.00. According to ...

Jefferies Sticks to Its Sell Rating for Fresenius Medical Care AG & Co. KGaA (0H9X)

Bernstein analyst Susannah Ludwig maintained a Hold rating on Fresenius Medical Care AG & Co. KGaA today and set a price target of €44.65. Accordin...

Fresenius Medical Care AG & Co. KGaA (0H9X) Gets a Hold from Bernstein

J.P. Morgan analyst David Adlington maintained a Sell rating on Fresenius Medical Care AG & Co. KGaA today and set a price target of €37.40. Accord...

Fresenius Medical Care AG & Co. KGaA (0H9X) Gets a Sell from J.P. Morgan

In a report released today, Graham Doyle from UBS maintained a Sell rating on Fresenius Medical Care AG & Co. KGaA, with a price target of €37.00. ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FMS	$24.68	+2.53%	618.67K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FMS	$24.68	+2.5%	618.67K
3
4
5
6

FMS

FMS

Get Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an) Data in Excel

Get Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an) Data in Excel